Dogwood Therapeutics (DWTX) Retained Earnings (2020 - 2026)

Dogwood Therapeutics has reported Retained Earnings for 7 years, with the latest figure at $196.2 million in Q2 2026.

• On a quarterly basis, Retained Earnings rose 321.62% year-over-year to $196.2 million in Q2 2026; TTM through Jun 2026 was $196.2 million, a 321.62% increase from a year earlier, with the FY2025 full-year figure at $183.9 million, up 349.06% from the prior year.
• Retained Earnings was $196.2 million for Q2 2026 at Dogwood Therapeutics, roughly flat from $195.7 million in the prior quarter.
• The five-year high for Retained Earnings was $196.2 million in Q2 2026, with the low at -$104.3 million in Q3 2025.
• Average Retained Earnings over 5 years is $51.5 million, with a median of $63.9 million recorded in 2023.
• The largest YoY upside for Retained Earnings was 349.06% in 2025 against a maximum downside of 254.88% in 2025.
• Over 5 years, Retained Earnings stood at $63.5 million in 2022, then grew by 3.27% to $65.6 million in 2023, then plunged by 212.57% to -$73.8 million in 2024, then soared by 349.06% to $183.9 million in 2025, then gained by 6.74% to $196.2 million in 2026.
• The last three Retained Earnings figures came in at $196.2 million (Q2 2026), $195.7 million (Q1 2026), and $183.9 million (Q4 2025), per Business Quant data.